Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model

• Libin Rong ,

  Contributed equally to this work with: Libin Rong, Jeremie Guedj, Harel Dahari

  Affiliation Department of Mathematics and Statistics and Center for Biomedical Research, Oakland University, Rochester, Michigan, United States of America

  ⨯
• Jeremie Guedj ,

  Contributed equally to this work with: Libin Rong, Jeremie Guedj, Harel Dahari

  Affiliations Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America, University Paris Diderot, Sorbonne Paris Cite, 75018 Paris, France, INSERM, UMR 738, 75018 Paris, France

  ⨯
• Harel Dahari ,

  Contributed equally to this work with: Libin Rong, Jeremie Guedj, Harel Dahari

  Affiliations Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, United States of America, Department of Medicine, Loyola University Chicago, Chicago, Illinois, United States of America

  ⨯
• Daniel J. Coffield Jr,

  Affiliation University of Michigan-Flint, Mathematics Department, Flint, Michigan, United States of America

  ⨯
• Micha Levi,

  Current address: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States of America.

  Affiliation Clinical Pharmacology, Pharma Research and Early Development, Roche, Nutley, New Jersey, United States of America

  ⨯
• Patrick Smith,

  Affiliation Clinical Pharmacology, Pharma Research and Early Development, Roche, Nutley, New Jersey, United States of America

  ⨯
• Alan S. Perelson

  * E-mail: asp@lanl.gov

  Affiliation Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America

  ⨯